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Results: A beta regression model best described DAD disease progression. The estimated treatment
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use, baseline disease status, and YSO had significant effects on disease progression rate, measured by
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Alzheimer’s disease (AD) progression varies among
different individuals, advancing from normal to prodromal
predementia, mild cognitive impairment, and dementia [1].
Currently available AD treatments mainly provide tempo-
rary enhancement of impaired neurotransmitter systems to
maximize remaining activity in disease-affected neuronal
populations [2–4]. They do not address underlying disease
process or progression of cognitive and functional decline.
With a goal of expanding treatment options for AD
population, development of new disease-modifyingimer’s Association. This is an open access article under the CC BY-NC-ND
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ology and change the course of AD, are underway.
Population disease progression modeling is an efficient
way to comprehensively integrate and use available informa-
tion. Simulation models applied to normal individuals, and
those with mild cognitive impairment or AD, are a key
step in the early detection and tracking of AD. In this
context, disease progression models focusing on cognitive
deterioration, as measured by a longitudinal response using
the AD assessment scale-cognitive subscale (ADAS-cog),
are well-accepted [5–9]. However, models characterizing
functional decline in AD are not available to date.
Disability assessment for dementia (DAD) scale is an
important and convenient tool to assess functional impair-
ment, a core symptom of AD often measured by loss of abil-
ity to perform activities of daily living. The DAD scale is
easy and quick to administer, taking ,15 minutes without
any requirement of a particular setting nor does it require
any special equipment. Another advantage of this scale is
that it does not require any particular expertise or extensive
training for administration. A user guide is available to
ensure proper administration and scoring of the instrument
[10]. In two phase-3 studies, bapineuzumab, an anti-
amyloid b monoclonal antibody, was investigated for its
therapeutic effect on cognitive and functional decline in
mild-to-moderate AD [11]. However, efficacy was not
demonstrated in either study. The goal of the current analysis
was to model the disease progression, as measured by DAD
scores, using combined data from the two bapineuzumab
phase-3 studies to allow for a better understanding of the
changes in DAD scores during disease progression, baseline
factors affecting progression of DAD scores, and the rela-
tionship between bapineuzumab exposure and DAD score
progression.2. Methods
2.1. Clinical data
The data set used in this disease progression analysis
comprised pooled data from two phase-3 studies of bapineu-
zumab in patients with mild-to-moderate ADwhowere either
apolipoprotein E, E4 allele (APOE ε4) noncarriers (study 301,
NCT00574132) or carriers (study 302, NCT00575055). De-
tails of the inclusion/exclusion criteria and primary results
of the two studies are available in the literature [11]. The
DAD score was the primary functional outcome measure for
assessing clinical efficacy in studies 301 and 302, and DAD
assessments were performed at prescheduled time points i.e.
weeks 0, 13, 26, 39, 52, 65, and 78. The data set for this anal-
ysis included all DAD measurements from both studies with
an available date and time of testing.
2.2. Model development
Disease progression models were established using
NONMEM (version 7.1.0 with a GNU FORTRAN compiler;Icon Development Solutions, Ellicott city, MD, USA). Data
exploration and visualization were performed using R
(http://www.r-project.org; version 2.14.0) and Xpose pack-
age 4.0 (http://xpose.sourceforge.net).
2.2.1. Structural model
A mixed-effect beta regression model was selected after
testing 10 basic models available in the literature [5,7,12–
14]. The model selection criteria were (1) Akaike
information criterion; (2) goodness-of-fit diagnostics; and
(3) ill conditioning and overparameterization by inspecting
the eigenvalues of the covariance matrix (ratio of the largest
eigenvalue to the smallest eigenvalue to be ,1000).
The beta regression model assumed that DAD scores
follow a beta distribution as denoted by
yij
hi; q; twbetamijt; 12mijt
where yij is the response variable (0 yij 1, i.e., DAD/100)
for the ith patient (i5 1.m) at the jth time (j5 1.nj), mij is
the conditional expectation (mean) of the response process
(0, mij ,1), hi’s are the random effects following a multi-
variate normal distribution (hiw N[0, S], q’s are the fixed
effects (parameter coefficients), and t is the precision
parameter (t . 0). The expected mean response model for
DAD followed a linear progressionmodel (on the logit scale)
with an intercept (q0) and slope on time (q1):
log

mij
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
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The beta regression model requires data residing within
the range of 0–100 [15,16], and therefore yij were rescaled
by a small noise factor (d 5 0.01) to move the boundary
observations slightly away from the edges [16,17].
2.2.2. Placebo model
The placebo effect (defined as transient improvement in
function during the initial period of weeks to months after
the treatment) has not been characterized for DAD score pro-
gression in any past studies to date. The choice of structural
form of the placebo function was driven by prior knowledge
[5,18,19]. Inverse Bateman function (IBF) and exponential
functions were explored to test the presence of the placebo
effect for DAD scores.
2.2.3. Covariate model
To date, covariates affecting progression of DAD scores
remain unknown because of the knowledge gap in the pub-
lished literature. Previously known ADAS-Cog score
models [6,7] have identified age, APOE ε4 carrier status,
AD concomitant medications (cholinesterase inhibitors or/
and memantine), sex, and years since disease onset (YSO)
as potential factors influencing disease progression. Thus,
we preselected these covariates to be tested on both
intercept and slope of the beta regression model for the
DAD scores (Eq. 1).
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ination was performed to identify a parsimonious covariate
model [20]. Effects of covariates were considered significant
if the increase in objective function value (OFV) value was
.7.88 (P, .005) on its removal to avoid inclusion of insignif-
icant covariates into the model due to multiple comparisons.
2.2.4. Drug model: Bapineuzumab effect
The bapineuzumab effect on disease progression was
investigated at two different levels: treatment level to eval-
uate the treatment effect versus the placebo and individual
level to evaluate the exposure-response relationship using
individual pharmacokinetic or concentration data (e.g. area
under the serum concentration-time curve [AUC] or trough
serum concentration [Ctrough]) based on a population phar-
macokinetic model for bapineuzumab [21]. An exploratory
graphical analysis was first performed followed by a formal
model evaluation. The interaction between the drug effect
and other covariates (baseline disease status and APOE ε4
carrier status) was also tested.
Three sensitivity analyseswere performed to further inves-
tigate the exposure-response relationship. Because the pri-
mary clinical analysis was performed in the modified
intention-to-treat population (mITT, i.e. all randomized
patients who received at least one infusion or portion of an
infusion of study drug and who had a baseline and at least
one postbaseline assessment of the ADAS-Cog/11 total score
and DAD total score) but the beta regression model was
developed using the overall population, the first sensitivity
analysis was conducted to confirm the exposure-response
relationship in the primary analysis data set. In addition, the
DAD scores appear improved in the bapineuzumab group at
weeks 65 and 78 (Fig. 1) in study 301. However, suchFig. 1. Exploratory analysis for bapineuzumab treatment effect for studies 301 and
administered as 0.5 or 1.0 mg/kg infused intravenously for 1 hour/13 weeks for six
withmild-to-moderate AD; vertical error bar represents the standard deviation of thimprovementwas not observed for the concurrentlymeasured
coprimary end point (ADAS-cog scores), so it could have
been a spurious effect due to variability. Therefore, two
more sensitivity analyseswere performed to assess the impact
of the improvements in DAD scores at the end of weeks 65
and 78 in study 301 on the exposure-response relationship af-
ter excluding these data from the analysis (i.e. after excluding
only week 78 data for patients in bapineuzumab group in
study 301 and after excluding both weeks 65 and 78 data
for patients in bapineuzumab group in study 301).2.3. Missing data
An analysis to explore the mechanism for missing data
was performed. A grouped-time survival model was used
to model missing data [22,23].
Complementary log-log (clog-log) link function was used
because it yields a grouped-time proportional hazards
model, and this can be advantageous for interpreting model
parameters compared with other link functions (e.g. logit).2.4. Model evaluation
The beta regression model was evaluated using percentile
visual predictive check (VPC), where the level to which the
median prediction or/and extremes of 90% prediction interval
replicated themedian, 5th, and95thpercentiles of theobserved
data at respective time points (weeks 0, 13, 26, 39, 52, 65,
and 78),was evaluatedwith confidence intervals [24]. To facil-
itate the comparison of the observed data to the simulated data
in the VPC analysis, the missing data event was simulated
based on the conditional probability at each time point,
assuming a binomial distribution for the missing event.302: observed average (mean) DAD scores versus time. Bapineuzumab was
infusions in APOE ε4 noncarrier (study 301) or carrier (study 302) patients
e meanDAD scores. Abbreviation: DAD, disability assessment for dementia.
Table 1
Bapineuzumab steady-state exposure metrics considered in the exposure
response analyses
Bapineuzumab dose level n
Mean 6 standard deviation
Ctrough (mg/mL) AUC (mg d/mL)
Study 301—0.5 mg/kg 337 0.64 6 0.3 211.8 6 53
Study 301—1 mg/kg 329 1.26 6 0.6 412.6 6 94
Study 301—2 mg/kg* 141 1.77 6 0.9 608.5 6 161
Study 302—0.5 mg/kg 673 0.65 6 0.3 211.4 6 50
Abbreviations: Ctrough, trough serum concentration; AUC, area under the
serum concentration-time curve.
*Initially, therewas also a 2.0-mg/kg dose level in study 301, but this dose
level was discontinued as of protocol amendment 1. Patients who had
already been randomly assigned to bapineuzumab 2.0 mg/kg were treated
with 1.0 mg/kg for the remainder of the study. None of the patients
completed the study at the 2.0-mg/kg dose level.
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This analysis included data from 2452 patients from
studies 301 and 302, in which 972 patients were treated
with placebo and 1480 with bapineuzumab, and all patients
had at least 1 DAD measurement. Further details on patient
characteristics are described elsewhere [11]. Briefly, 46%
were men and 54% were women. The mean
age6 standard deviation was 72.66 9.0 years, and patients
had AD for a mean duration of 3.2 6 2.4 years. The mean
baseline mini mental state examination (MMSE) and DAD
scores were 21 6 3.2 and 80 6 19, respectively. Based on
mild versus moderate AD definitions of baseline MMSE
score 21 versus 20, respectively, 54% of patients hadTable 2
Parameter estimates of the beta regression model
Parameter estimates
Logit scale
Estimate 95% co
Baseline
Mild AD 2.23 2.14
Moderate AD 1.39 1.29
Covariates on baseline
Sex (men) 0.061 20.03
Use of memantine 20.318 20.41
Age (y) 20.020 20.02
YSO (y) 20.047 20.07
Progression rate (points/y) 20.006 20.009
Covariates on progression rate
MMSE 0.0013 0.001
Use of memantine or cholinesterase
inhibitors
20.0072 20.010
YSO (y) 0.0006 0.000
Exposure-response on progression rate
Mild AD, AUC (1000 mg d/mL) 0.0059 0.001
Moderate AD, AUC (1000 mg d/mL) 0.0026 20.002
SD of IIVon intercept 1.09 1.02
SD of IIVon slope 0.0002 0.000
Precision parameter 3.19 3.14
Abbreviations: AD, Alzheimer’s disease; YSO, years since onset of Alzheimer’s
concentration-time curve; SD, standard deviation; IIV, Interindividual variability;
NOTE. The parameter estimates for the beta regression model do not have a direc
in the model. Therefore, to facilitate interpretation, the marginal effect of covariamild AD and 46% had moderate AD. A total of 11.3%
patients were homozygous for the APOE ε4 allele, 33.5%
were APOE ε4 heterozygous, and 54.2% were APOE ε4
noncarriers. A total of 90.5% patients took AD concomitant
medications, i.e. 53% took acetylcholinesterase inhibitors
and memantine; 33% took acetylcholinesterase inhibitors
alone; and 4.4% took memantine alone.
In the two studies combined, 40% of all patients were
randomized to placebo, 41% were randomized to bapineu-
zumab 0.5 mg/kg, 13% were randomized to bapineuzu-
mab 1 mg/kg, and 6% were originally randomized to
bapineuzumab 2 mg/kg. After a protocol amendment in
April 2009, the 2 mg/kg dose in study 301 was reduced
to 1 mg/kg. The steady-state exposure to bapineuzumab
(AUC and Ctrough) over the duration of the studies is sum-
marized by bapineuzumab dose level in Table 1. The drug
exposure is nearly identical at 0.5 mg/kg in the APOE ε4
noncarriers (study 301) and carriers (study 302). The
exposure proportionally increased when dose increased
from 0.5 to 1 mg/kg. The exposure in patients randomized
to 2 mg/kg was approximately 40% higher than that in pa-
tients on 1 mg/kg.3.1. Population mean estimates of baseline and disease
progression according to DAD
The parameter estimates of the final model are summa-
rized in Table 2. The population mean of baseline DAD
score in a typical 74-year-old patient with mild AD (noOriginal scale
nfidence interval Estimate 95% confidence interval
2.32 90.29 89.49 91.04
1.49 80.06 78.48 81.55
0.15 1.52 20.67 3.70
20.23 27.95 210.22 25.68
20.01 20.49 20.61 20.37
20.03 21.17 21.66 20.68
20.003 27.58 211.25 23.91
0 0.0016 1.70 1.34 2.06
0 20.0044 29.39 213.00 25.77
3 0.0008 0.76 0.41 1.10
1 0.0107 7.72 1.48 13.96
2 0.0073 3.32 22.88 9.51
1.16 27.25 25.40 29.10
1 0.0002 0.226 0.183 0.269
3.24 — — —
disease; MMSE, mini mental state examination; AUC, area under the serum
DAD, disability assessment for dementia.
t interpretation on the original scale because of the logit transformation used
tes and rate of progression were evaluated at a DAD score of 50.
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80 for a patient with moderate AD. The progression rate for a
typical placebo patient with baseline MMSE score of 21,
YSO of 2.83 years, who did not take memantine or acetyl-
cholinesterase inhibitor (approximately 9.5% of the overall
patients) was 27.6 points/year.3.2. Covariate effects on disease progression parameters
Analysis of baseline covariates demonstrated that mem-
antine use, age, YSO, and baseline disease status (i.e. mild
or moderate AD) had statistically significant effects on base-
line DAD scores (P  .0005), whereas use of AD concomi-
tant medications (i.e. memantine or acetylcholinesterase
inhibitors), baseline disease status, and YSO had statistically
significant effects on the rate of disease progression as
measured by DAD scores (P, .0001). APOE ε4 carrier sta-
tus (homozygous vs. heterozygous or carrier vs. non-carrier)
had no significant effect on either the baseline DAD score or
the disease progression rate.
The baseline DAD score for patients taking memantine at
baseline was approximately 8.0 (95% confidence interval
[CI], 5.7–10.2) points lower than those not taking meman-
tine. The baseline DAD score decreased for each additional
year of having the disease by 0.5 (95% CI, 0.4–0.6) points
and 1.2 (95% CI, 0.7–1.7) points for older age and YSO at
baseline, respectively. The effect of sex was not significant
on baseline DAD score (P . .05).
Patients who had used AD concomitant medications at
baseline tended to have greater disease progression rate.
The progression rate of the DAD score was 17 points per
year for patients who were in the placebo arm and taking
memantine or acetylcholinesterase inhibitors (w90.5% of
study patients), as compared with 7.6 (95% CI, 3.9–11.5)
points/year for those not taking these AD concomitant med-
ications. It was reported that average decline in DAD was
approximately 15 points after a year for patients with mild-
to-moderate AD dementia [25]. The mean change in DAD
score after a year appeared to be approximately 10–12 points
in a phase-2 bapineuzumab study [26]. Our result for patients
is consistent with the published values. Patients with less dis-
ease severity at baseline had slower rates of disease progres-
sion. For every unit of increase in MMSE score, the DAD
score progression rate decreased by approximately 1.7
(95% CI, 1.3–2.1) points/year. In addition, patients with
higher YSO at baseline had slower DAD score progression
rates (0.8 points/year/YSO [95% CI, 0.4–1.1]).3.3. Placebo model
Placebo models with three-parameter IBF function or
two-parameter exponential function were tested, but neither
of them significantly improved the DAD disease progression
model. Both placebo models led to a decrease of 4 points in
OFV for the disease progression model (P 5 .26 for three-
parameter IBF model and P 5 .14 for two-parameter expo-nential model), suggesting that a placebo effect (defined as
transient improvement in function) was minimal in both
studies. However, the placebo effect might not be well-
estimated in this model due to the sparse data.3.4. Bapineuzumab effect3.4.1. Treatment effect
Disease progression profiles appeared to be similar for
bapineuzumab and placebo groups (Fig. 1). However, the ba-
pineuzumab group tended to have a slower DAD score pro-
gression rate after week 52. There was no apparent
difference in the trend for APOE ε4 carriers and noncarriers.
After adding treatment information to the beta regression
model, OFVof the model improved by 2.7 points (P 5 .1),
indicating treatment effect was not a significant factor
affecting DAD disease progression. This observation is
consistent with the lack of efficacy observed in the studies,
albeit the estimated effect was directionally consistent
with the hypothesized drug effect.
3.4.2. Exposure-response relationship of bapineuzumab
Fig. 2 indicates that the exposure-response relationship
was apparent in patients with mild AD in study 301
(APOE ε4 non-carriers), and with increase in drug exposure,
DAD progression rate slowed. In both bapineuzumab
exposed groups, separation of disease progression profiles
was observed after week 39 versus placebo group. Such a
trend was less apparent in study 302 (APOE ε4 carriers)
because it tested only the low dose and in moderate AD
patients from study 301 (APOE ε4 noncarriers).
The beta regression model revealed a marginal but posi-
tive association between bapineuzumab exposure (i.e.,
AUC) and slowing of disease progression rate. The DAD
score progression rate decreased by 7.7 (95% CI, 1.5–14)
points/year and 3.3 (95% CI, 22.9 to 9.5) points/year for
every 1000-mg d/mL AUC increase in patients with mild
AD and moderate AD, respectively (Table 2). The estimated
reduction in progression rate would be 3.2 points/year and
1.4 points/year at 1 mg/kg (AUC 5 412.6 mg d/mL) for
patients with mild and moderate AD, respectively. The anal-
ysis suggested that the exposure-response relationship was
similar regardless of APOE ε4 carrier status (carrier or
noncarrier) as the interaction between APOE ε4 carrier sta-
tus and bapineuzumab exposure was not significant
(P 5 .29).
In the first sensitivity analysis, the estimated exposure-
response in mild AD patients was only 3% higher in the
mITT population than in the overall population (Table 3),
suggesting that the model parameter estimation was not
sensitive to the exclusion of patients for the mITT popula-
tion. After exclusion of week 78 data, the exposure-
response relationship in patients with mild AD was reduced
slightly by 5.9%. In contrast, after excluding the data from
weeks 65 and 78, the exposure-response relationship
Fig. 2. Exposure-response relationship for bapineuzumab by study and severity of Alzheimer’s disease: Observed average (mean) DAD scores versus time.
Steady-state AUC is used. Patients treated with bapineuzumab were grouped by median AUC for each study. Abbreviations: DAD, disability assessment for
dementia; AUC, area under the serum concentration-time curve.
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that the possible effect of bapineuzumab exposure on slow-
ing DAD progression in patients with mild AD was not
caused by the improvement in DAD scores at the end of
study. This is not unexpected because this trend was
apparent as early as in week 39 in patients with mild AD
in study 301 (Fig. 2).3.5. Missing data analysis
The probability of missingness was significantly
(P , .0001) dependent on DAD score before the event and
patient’s baseline age. The hazards of missing decreased
by 2% for every unit increase in DAD score before the event,
whereas it increased by 2.4% for every year of increase in
age. This finding confirmed that “missing completely atrandom” was not the missing data mechanism and that
missing at random may be a more reasonable assumption,
which was consistent with the assumption for the primary
statistical analysis (mixed-effect model with repeated
measure).3.6. Model evaluation
The VPC suggested that the disease progression model
not only described the overall longitudinal progression of
the DAD scores well (Fig. 3A) but also adequately described
the exposure-response relationship between bapineuzumab
exposure and longitudinal DAD score progression
(Fig. 3B). Additional VPC plots for patients with mild and
moderate AD are provided in Supplementary Figs. 1 and
2, respectively.
Table 3
Parameter estimates of exposure-response for bapineuzumab from the sensitivity analyses
Data set
Exposure-response on logit scale
% change versus reference 0 within 95% CIEstimate 95% CI
Mild AD
Overall population 0.0059 0.0011 0.0107 Reference No
mITT population 0.0061 0.0013 0.0109 3.0 No
Week 78* 0.0056 0.0004 0.0108 25.9 No
Weeks 65 and 78y 0.0073 0.0016 0.0129 22.4 No
Moderate AD
Overall population 0.0026 20.0022 0.0073 Reference Yes
mITT population 0.0021 20.0027 0.0068 219.2 Yes
Week 78* 0.0039 20.0010 0.0089 54.5 Yes
Weeks 65 and 78y 0.0034 20.0019 0.0086 31.4 Yes
Abbreviations: CI, confidence interval; AD, Alzheimer’s disease; mITT, modified intention-to-treat.
*Week 78 5 population after excluding all week 78 data for patients in bapineuzumab group in study 301.
yWeeks 65 and 78 5 population after excluding all week 65 and 78 data for patients in the bapineuzumab group in study 301.
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This modeling approach attempts to provide a novel
methodological framework to describe and interpret AD
progression in terms of DAD scores and of the effects of
covariates on disease progression. The impact of covariates
on the progression of DAD scores has not yet been character-
ized in the literature for disease progression models, and thus
remains unknown. Our analysis addresses this gap by iden-
tifying the covariates (demographics and baseline character-
istics) contributing to the variability in disease progression
rate and baseline disease status among mild-to-moderateFig. 3. (A). Visual predictive check for the beta regression model based on the ov
indicated by the open circles represent the 95th, 50th, and 5th percentiles of the obse
lines are themedianmodel-based prediction for the 95th, 50th, and 5th percentiles, r
are the 90% confidence intervals of the corresponding percentiles of the simulations
the simulations. (B). Stratified visual predictive check for patients with mild Alzh
represent the mean of the observed data. The curves indicated by the lines are the m
are the 90% confidence intervals of the corresponding predictions based on the mod
Abbreviations: DAD, disability assessment for dementia; AUC, area under the seAD patients. However, as this is the first attempt to model
the longitudinal progression of DAD scores, previously
identified covariates on cognitive tests (e.g. ADAS-cog
score) were evaluated. Similar approach has been used
when modeling other AD functional measures [27]. Because
of the potential difference between the functional and cogni-
tive progression of the AD, other covariates that were not
included in the current analysis may also affect the function
in AD patients.
Beta regression models were recently qualified as a quan-
titative clinical trial simulation tool for ADAS-cog/11 by theerall data from studies 301 and 302. The upper, middle, and lower profiles
rved data, respectively. The upper, middle, and lower curves indicated by the
espectively, and these predictions account for missing data. The shaded areas
based on themodel. The beta regressionmodel listed in Table 2 was used for
eimer’s disease in study 301: exposure-response relationship. The symbols
ean model-based predictions that account for missing data. The shaded areas
el. The beta regression model listed in Table 2 was used for the simulations.
rum concentration-time curve [11].
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Agency for mild-to-moderate AD [28,29]. The current
analysis suggested that beta regression models are also
sensible modeling choice for DAD scores. Similar to
ADAS-cog scores, DAD scores also represent a bounded
outcome. Beta regression models have been shown to well
describe and predict the bounded outcome data with
nonlinear mean and the heteroscedastic variance due to the
ceiling/floor effects [30,31].
Because AD patients may be able to learn aspects of
cognition tests such as ADAS-cog test, and complicated im-
plementation of cognition tests may cause rater’s bias, tran-
sient placebo improvement has often been found on
cognitive end points. A placebo effect was not observed in
the current analysis on the functional DAD test. This may
be suggestive that functional tests may be less susceptible
to the learning effects and rater’s bias. Therefore, modeling
functional AD measures such as DAD score could provide
additional useful information that could not be obtained
from ADAS-Cog disease progression models.
The analyses based on either the treatment groups or
the individual bapineuzumab exposure levels demon-
strated a trend of improvement of function in mild AD
patients after the treatment with bapineuzumab. The trend
was not found to be statistically significant among treat-
ment groups, whereas the individual exposure-response
relationship appeared to be marginally significant. This
is probably because individual exposure levels could pro-
vide richer information regarding the drug exposure than
the dichotomous treatment groups. According to the sensi-
tivity analyses, the exposure-response trend was not
attributable to the increase in the DAD scores after
week 65. In patients with moderate AD, the directionality
of the estimated bapineuzumab effect was consistent with
that for the mild AD patients, but the magnitude of the
estimated bapineuzumab effect was less pronounced
compared with that in mild AD.5. Conclusion
A beta regression logistic model best described disease
progression as measured by DAD scores for patients with
mild-to-moderate AD in studies 301 and 302. The model
suggested a possible effect of bapineuzumab exposure on
DAD progression, i.e. disease progression according to the
DAD score decreased with increased bapineuzumab expo-
sure. The exposure-response relationship was similar
regardless of APOE ε4 status but more pronounced in
patients with mild AD. Baseline disease status, age, meman-
tine use, and disease duration had significant effects on base-
line DAD scores. Use of AD concomitant medications,
baseline disease status (mild AD vs. moderate AD), and dis-
ease duration had significant effects on DAD score disease
progression rate. The relation to AD comedication use is
likely due to patients with faster progression rates being
more likely to receive treatment for AD.Acknowledgments
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1. Systemic review: The authors developed a disease
progression model based on pooled disability assess-
ment for dementia (DAD) score data from two
phase-3 studies of bapineuzumab in patients with
mild-to-moderate Alzheimer’s Disease (AD) who
were either APOE ε4 noncarriers or carriers.
2. Interpretation: The model suggested a possible effect
of bapineuzumab exposure on DAD progression, i.e.
disease progression according to the DAD score
decreased with increased bapineuzumab exposure.
The exposure-response relationship was similar
regardless of APOE ε4 status but more pronounced in
patients with mild AD. Baseline disease status, age,
memantine use, and disease duration had significant
effects on baseline DAD scores. Use of AD
concomitant medications, baseline disease status
(mild AD vs. moderate AD), and disease duration
had significant effects on DAD score disease pro-
gression rate.
3. Future directions: This modeling approach provides
a novel methodological framework to describe and
interpret AD progression in terms of DAD scores
and of the effects of covariates on disease progres-
sion, which could assist in the design of future clin-
ical studies.
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